-

Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland

  • Dexcom’s first manufacturing facility in Europe will ensure the flow of products throughout EMEA
  • New manufacturing site will create over 1,000 local jobs, including across finance, HR and engineering disciplines

GALWAY, Ireland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing facility, located in Athenry, Co. Galway. This marks the first step in the realisation of this facility, which will bring more than 1,000 jobs to the area and represents one of the biggest single private sector investments ever in the West of Ireland.

Dexcom’s first manufacturing facility in Europe will ensure the flow of products throughout EMEA, with the potential to lower the cost of goods and improve sustainability by decreasing delivery time in transit. The new facility will have the capacity to produce millions of Dexcom rtCGM sensors each year, helping to improve the lives of people with diabetes in EMEA.

“This facility is strategically located in Europe, for Europe,” said Alex Moussa, Senior Vice President & General Manager EMEA and LATAM at Dexcom. “This development demonstrates our commitment to sustainable growth and operational excellence in EMEA, as well as to the people we serve. This is only the beginning; we’re truly excited for what’s to come.”

The 1,000 available jobs include support in finance, HR, as well as a variety of engineering roles, ranging from leadership to graduate positions. Dexcom intends to build strong links with the local universities in Galway and nearby counties, particularly around engineering and quality assurance courses. In an additional boost to the local economy, it is expected that for every job created by Dexcom a further 1 – 1.7 jobs will be created indirectly*.

“At Dexcom, we pride ourselves on attracting and retaining world-class talent, which Ireland provides,” said Simone Würzner, Senior Director Human Resources EMEA. “As an organisation, we empower people to better manage their health with our life-changing continuous glucose monitoring technology. The opportunity this provides to our team is endless, offering challenging and meaningful work that truly makes a difference in people’s lives. We’re looking forward to building our team in Ireland as we enter the next phase of Dexcom in Europe.”

Dexcom is also further demonstrating its long-term commitment to Europe, and specifically the West of Ireland by announcing a 12-year naming-rights partnership with Connacht Rugby. From today, ‘The Sportsground’ will be known as ‘Dexcom Stadium,’ which has been the home of Connacht Rugby since 1927. For information about Dexcom job openings in Athenry go to: careers.dexcom.com/careers.

To learn more about Dexcom or to get started with Dexcom CGM today, visit Dexcom.com.

About DexCom, Inc.

DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

*Statistic provided by IDA

Contacts

Kate Lynch, Allison for Dexcom
Kate.Lynch@allisonworldwide.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Kate Lynch, Allison for Dexcom
Kate.Lynch@allisonworldwide.com

More News From DexCom, Inc.

Dexcom Further Advances Vision of Glucose Biosensing for All

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h...

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e...
Back to Newsroom